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Abstract
Background: The human apurinic/apyrimidinic endonuclease 1/Redox effector factor-1 (APE1/Ref-1) is implicated in
tumor development and progression. Recently, the APE1/Ref-1 promoter -141T/G variant (rs1760944) has been
reported to be associated with lung cancer risk. Given the importance of APE1/Ref-1 in both DNA repair and redox
activity, we speculate that the -141T/G polymorphism may confer individual susceptibility to gliomas or its
subtypes.
Methods: The APE1/Ref-1 -141T/G polymorphism was analyzed in a case-control study including 766 glioma
patients (among them 241 glioblastoma, 284 astrocytomas except for glioblastoma and 241 other gliomas) and
824 cancer-free controls from eastern China. Genotyping was performed with Sequenom MassARRAY iPLEX
platform by use of allele-specific MALDI-TOF mass spectrometry assay. We estimated odds ratios (ORs) and 95%
confidence intervals (95% CIs) using unconditional logistic regression. A test of trend was calculated using the
genotype as an ordinal variable in the regression model. For each statistically significant association identified, we
estimated the false positive reporting probability (FPRP). FPRP values less than 0.2 were consider to indicate robust
associations.
Results: The significant association between the APE1/Ref-1 promoter -141T/G polymorphism and glioma risk was
not observed. However, the stratified analysis by histology revealed the variant allele G significantly decreased
glioblastoma risk (OR = 0.80, 95% CI = 0.65-0.98, P = 0.032). Individuals with the homozygous -141GG genotype
exhibited 46% reduced risk of glioblastoma (adjusted OR = 0.54, 95% CI 0.34-0.87, P = 0.012), compared with the
TT homozygote. This result remained robust given the prior probabilities of 25% (FPRP = 0.052) and 10% (FPRP =
0.140), but not with a prior probability of 1% (FPRP = 0.643). The P-associated with the trend test was 0.014.
Conclusions: Our results suggest that a specific genetic variant located in the APE1/Ref-1 promoter may modulate
risk of glioblastoma, but not for other histological gliomas. Larger studies with more APE1 polymorphisms are
required to validate these preliminary findings.
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Gliomas present a group of primary brain tumors that ori-
ginate from glia (from the Greek for “glue”), accounting
for more than 40% of the newly diagnosed brain tumors
[1]. In accordance with their clinicopathological features,
gliomas are generally classified into astrocytomas, oligo-
dendrogliomas, mixed oligoastrocytomas and ependymo-
mas [2]. Glioblastoma multiforme (GBM), a subtype of
gliomas, is the most common and the most malignant
glioma (World Health Organization [WHO] grade IV)
with median survival of only 12-15 months under the cur-
rent standard of care [3]. Except high-dose ionizing radia-
tion (IR), the etiology of sporadic gliomas is still poorly
understood [2]. However, only a small proportion of
exposed individuals will develop gliomas, suggesting a
genetic predisposition of gliomas.
Exposure to IR can result in various types of DNA
damage that cause cells to turn cancerous. Cells respond
to this damage through the activation of various DNA
repair pathways, and each pathway involves numerous
molecules. The human apurinic/apyrimidinic endonu-
clease 1/Redox effector factor-1 (APE1/Ref-1)p l a y sa
central role in the base excision repair pathway for the
repair of DNA damage generated by alkylation, oxidata-
tion and IR [4]. As an endonuclease, APE1/Ref-1 hydro-
lyzes the phosphodiester bond 5’ to abasic sites, leaving
an o r m a l3 ’-hydroxyl group and 5’-deoxyribose phos-
phate terminus for DNA repair synthesis [5-7]. In
addition to AP endonuclease activity, APE1/Ref-1 has
3’-repir diesterase or phosphatase activity [8], which is
important in repairing DNA damage caused by radia-
tion. Furthermore, APE1/Ref-1 also possesses a 3’-5’
exonuclease activity, reported to play a role in the exci-
sion of deoxyribonucleoside analogs from DNA [9,10].
Besides its role in DNA repair, APE1Ref-1 also functions
as a redox activator of numerous cellular transcription
factors, such as AP-1, NF-кB, p53, Egr-1, c-Myb, HIF-
1a, HLF, and Pax-8, that are thought to be important in
carcinogenesis [11]. Knocking out APE1/Ref-1 in mice
causes postimplanatation embryonic lethality [12,13]
and any attempt to isolate stable APE1/Ref-1 - knockout
cell lines has been so far unsuccessful, clearly indicating
that the importance of its function to cell survival and
propagation.
The Human APE1/Ref-1 is polymorphic. The most
frequently evaluated variant in relation to cancer risk is
the single nucleotide polymorphism (SNP) at codon 148
of exon 5 of the APE1/Ref-1 gene (i.e. Asp148Glu;
D148E; rs1130409). Although the APE1/Ref-1Asp148Glu
polymorphism doses not result in reduced endonuclease
activity [14], the Glu allele may have higher sensitivity
to IR [15]. Genetic epidemiologic studies have showed
that the APE1/Ref-1 Glu allele alone was associated
with an increased risk of breast caner [16] and gastric
cancer [17], and with a decreased risk of cutaneous
melanoma [18] and gliomas [19], whereas no associations
were found in prostate cancer [20], pancreatic cancer
[21] and glioblastoma [22]. For lung cancer, Glu allele
homozygote had an increased risk in one small study
[23], but no association was observed in other six larger
studies [24-29]. Other APE1/Ref-1 polymorphisms have
also been evaluated for altered cancer susceptibility. One
study reported that the non-synonymous SNP Ile64Val
(rs2307486) was associated with a decreased risk of
non-small cell lung cancer (NSCLC) [27]. Another amino
acid substitutive variant, Gln51His (rs1048945), was eval-
uated in two studies; no association was found for either
prostate cancer [20] or lung cancer [27]. Moreover, the
polymorphisms in the APE1/Ref-1 gene and other DNA
repair genes may interact to have joint effects on risk of
certain cancers [18-21,23-28].
Notably, these previous studies mainly focused on the
non-synonymous SNPs of the APE1/Ref-1 gene. The
role of APE1/Ref-1 promoter polymorphisms in cancer
risk was little studied. Recently, the -141T/G variant
(rs1760944) in the APE1/Ref-1 promoter has been
reported to be associated with a decreased risk of lung
cancer in Chinese populations [28,29]. In view of the
importance of APE1/Ref-1 in both DNA repair and
redox activity, we speculate that APE1/Ref-1 -141T/G
variant may also confer individual susceptibility to glio-
mas or its certain subtypes. To test this hypothesis, the
APE1 promoter polymorphism was investigated in a
hospital-based case-control study with 766 glioma
patients and 824 cancer-free controls from eastern
China. Odds ratios (OR) were determined for all study
patients and for those with histological subtypes of glio-
blastoma (241 cases), astrocytomas except for glioblas-
toma (284 cases), and other gliomas (241 cases).
Methods
Study population
The current study included 766 glioma patients and 824
healthy cancer-free controls. According to histological
diagnosis, the glioma patients were stratified into three
subgroups: 241 glioblastomas, 284 astrocytomas except
for glioblastoma and 241 other gliomas. The subject
enrollment commenced in October 2004 and is ongoing.
All newly diagnosed glioma cases were inpatients for
tumor resection at the Neurosurgery Department of
Huashan Hospital of Fudan University, Shanghai, China.
This hospital is the biggest center of neurosurgery in
the east of China [30]. Histopathological diagnoses of
potentially eligible cases were carried out on the basis
of the biopsies or resected specimens in the Department
of Neuropathology of the same hospital. Although there
were no restrictions on age, gender and histology,
patients who had previous cancers and/or previous
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free control subjects were randomly recruited from
annual checkup visitors (80%) and trauma outpatients
(20%) at the same hospital during the similar time per-
iod and were frequency- matched to cases by gender,
age (±5 years) and residence (urban or rural). The
included controls self-reported no history of malignan-
cies, genetic neurologic disorders and radiotherapy/che-
motherapy. No evidence of demographic differences was
detected between these trauma outpatients and the
annual checkup subjects (data not shown). All partici-
pants were genetically unrelated ethnic Han Chinese
people from Shanghai and its surrounding regions
including Jiangsu, Zhejiang, and Anhui provinces.
Each eligible subject was face-to-face interviewed by a
trained personnel who was blinded to the case-control
status with a shortened structured questionnaire, which
was adapted from the original version provided by
Dr. Melissa Bondy for brain study in the Department of
Epidemiology at M.D. Anderson Cancer center, to
obtain data on demographic factors, smoking status,
radiation exposure, family history of cancer and other
factors. Each subject provided the informed consent and
donated 3-5 ml of peripheral blood. As a result, DNA
samples and questionnaires were available from 766
case and 824 control subjects representing an 85.7% and
79.2% of all eligible case and control subjects, respec-
tively. The research protocol was approved by the Ethics
Committee for Human Subject Research of Fudan
University.
Genotyping
Genomic DNA was extracted from whole-blood samples
using the Qiagen Blood Kit (Qiagen, Chatsworth, CA,
USA), according to the manufacturer’s instructions.
After extraction, genomic DNA was diluted to a final
concentration of 15-20 ng/μl for the genotyping assays.
Polymorphism spanning fragments were amplified by
the polymerase chain reaction (PCR) and performed
genotyping with Sequenom MassARRAY iPLEX plat-
form by use of allele-specific MALDI-TOF mass spec-
trometry assay [31]. Primers for amplification and
extension reactions were designed using MassARRAY
Assay Design Version 3.1 software (Sequenom, San
Diego, CA). And SNP genotypes were obtained accord-
ing to the iPLEX protocol provided by manufacturer.
Genotyping quality was examined by a detailed QC pro-
cedure consisting of > 95% successful call rate, duplicate
calling of genotypes, internal positive control samples
and Hardy-Weinberg Equilibrium (HWE) testing.
Statistical analysis
Differences in demographic variables, smoking status,
family history of cancer, and grouped allele and genotype
frequencies between cases and controls were compared
by the c
2 test (df = 2). The Hardy-Weinberg Equilibrium
was determined using the standard c
2 test (df =1 )t o
compare the observed frequency with the expected fre-
quency in controls. To estimate the association between
the APE1/Ref-1 -141T/G variant and risk of gliomas,
odds ratios and 95% confidence intervals (95% CI) were
calculated using unconditional logistic regression with
adjustment for age and gender. The homozygosity with
the more frequent allele among controls was set as the
reference group. A test of trend was calculated by treat-
ing the three genotypes (major allele homozygous, het-
erozygous and variant allele homozygous) as ordinal
variables in the regression models. Furthermore, we per-
formed stratified analyses for the APE1/Ref-1 -141T/G
polymorphism by age (two groups: < 18 years and > 18
years), gender, smoking status, family history of cancer
and histologic type. The SPSS 15.0 software (SPSS, Chi-
cago, IL, USA) was used for all statistical analyses. All P
values presented were two sided, and a level of P <0 . 0 5
was considered statistically significant.
To further assess the probability of a spurious associa-
tion due to multiple testing, we calculate the false-
positive report probability (FPRP) for a SNP from an
estimated OR and 95% CIs using the methodology
described by Wacholder et al [32]. To assign a prior
probability for the APE1/Ref-1 -141T/G variant, we con-
sidered that the genetic variant has been previously
shown to influence expression of the APE1/Ref-1 gene
[28,29] and has been previously reported to be asso-
ciated with lung cancer risk [28,29]. In the light of this,
prior probabilities of 25% (and 10%) were assigned.
However, no previous studies have been reported on the
association between the APE1/Ref-1 promoter poly-
morphism and glioma risk. Hence, we selected more
conservative prior probabilities, 1% and 10%. In accor-
dance with Wacholder et al [32], a standard FPRP cut-
off of < 0.5 was selected with a cut-off of < 0.2 being
considered more stringent.
Results
Characteristics of study population
The details of selected characteristics of 766 glioma cases
ad 824 control subjects have been shown in Table 1.
The differences in the distributions of age, gender and
smoking status between cases and controls were not
statistically significant (P = 0.353, 0.919, and 0.535,
respectively). The mean age of cases (42.4 years) at
diagnosis was slightly older than the reference age for
controls (41.5 years). 59.1% cases and 59.9% controls
were male. As shown in the previous study, the
c a s e sw e r em o r el i k e l yt or e p o r tah i s t o r yo fc a n c e ri n
first-degree relativest h a nc o n t r o l s( 2 0 . 3 %vs. 15.5%;
P = 0.027). Among 766 glioma cases, 241 were
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and 241 other gliomas (Table 1).
The genotyping success rate was 98.5%. The observed
G allele frequency for rs1760944 T/G SNP in controls
was 45.0%, which was similar to that reported in Hap-
Map database for Chinese Han population. Genotype
frequencies of rs1760944 T/G SNP among the controls
did not differ significantly from those expected under
HWE (P = 0.262). Because there was no difference in
allele and genotype frequency distribution between two
control groups, “annual check-up subjects” and “trauma
outpatients” (data not shown), we combined these two
control groups for subsequent analyses.
APE1/Ref-1 rs1760944 and risk of gliomas
Allele and genotype frequencies and associated ORs (95%
CI) for glioma cases and controls are presented in Table 2.
The variant allele G was 45.0% in controls and 42.8% in
cases. The frequencies of the TT, TG and GG genotypes
of APE1/Ref-1 rs1760944 were 29.0%, 52.0% and19.0% in
controls, and 30.4%, 51.2% and 16.3% in cases, respec-
tively. No significant differences were found in allele and
genotype distributions of APE1Ref-1 rs1760944 T/G
between glioma cases and controls (P = 0.220 and 0.410,
respectively). In logistic regression analysis, neither the
homozygous -141GG nor heterozygous TG genotype was
associated with risk of gliomas in overall population.
Further analysis showed that rs1760944 T/G genotypes
were not associated with gender, age, smoking status, or
family history of cancer (Table 3).
APE1/Ref-1 rs1760944 and risk of gliomas stratified by
histology
Next, we performed the stratified analysis for APE1/Ref-1
rs1760944 by glioma histology. As shown in Table 4, sta-
tistically significant differences were observed in allele and
genotype distributions of rs1760944 T/G between glioblas-
toma patients and control subjects (P = 0.032 and 0.041,
respectively). Overall, the variant G allele was associated
with a decreased risk of glioblastoma compared with the T
allele (OR = 0.80, 95% CI = 0.65-0.98, P = 0.032). Indivi-
duals with the homozygous -141GG genotype exhibited
46% reduced risk of glioblastoma (adjusted OR = 0.54,
95% CI = 0.34-0.87, P = 0.012), compared with the TT
homozygote. According to the criteria suggested by
Wacholder et al [32], this result remained robust given the
appropriate prior probability of 25% (FPRP = 0.052) and
10% (FPRP = 0.140), but not with a prior probability of 1%
(FPRP = 0.643). The P-associated with the trend test was
0.014 (P for trend = 0.014). However, no significant asso-
ciation of rs1760944 with risk of low-grade astrocytomas
(astrocytomas except for glioblastoma) and other gliomas
was found in this study. As the number of glioblastoma
subjects was not large enough for stratification analysis,
we did not further evaluate the association between the
rs1760944 T/G and risk for glioblastoma by age, gender,
smoking status and family history of cancer.
Post-hoc power calculation
We also performed post-hoc power calculation based on
the observed variant allele frequencies in both control
Table 1 Frequency distribution of selected characteristics
of study subjects by the case-control status
Variable Controls (n = 824) Cases (n = 766) P value
a
No. (%) No. (%)
Age (mean ± SD) (y) 41.5 ± 18.4 42.2 ± 16.0 0.439
Age (y) 0.353
Children(≤18) 60(7.3) 66(8.6)
Adults(>18) 764(92.7) 700(91.4)
Gender 0.919
Male 490(59.5) 453(59.1)
Female 334(40.5) 313(40.9)
Smoking status 0.535
Never 490(60.6) 394(62.0)
Former 120(14.8) 81(12.8)
Current 199(24.6) 160(25.2)
Family history of cancer
No 626(84.5) 496(79.7) 0.027
Yes 115(15.5) 126(20.3)
Histology
Glioblastoma 241(31.5)
Astrocytomas
b 284(37.0)
Other gliomas
c 241(31.5)
aTwo-sided c
2 test.
bAstrocytomas including diffuse astrocytomas, anaplastic astrocytomas and
other astrocytomas.
cOther gliomas including oligodendrogliomas, enpendymomas, or mixed
glioma.
Table 2 Analysis of association between APE1/Ref-1
rs1760944 and risk of all gliomas
rs1760944 Controls (824) All Gliomas (766)
No. (%) No. (%) P
a OR (95% CI)
b P
c
Alleles
T 898 (55.0) 858 (57.2) 0.220 1.00 (reference) 0.220
G 734 (45.0) 642 (42.8) 0.91 (0.79-1.05)
Genotypes
TT 237 (29.0) 233 (30.4) 0.410 1.00 (reference)
TG 424 (52.0) 392 (51.2) 0.94 (0.75-1.18) 0.588
GG 155 (19.0) 125 (16.3) 0.81 (0.61-1.10) 0.183
P
d for trend = 0.199
aAllele and genotype frequencies in cases and controls were compared using
c
2 test.
bAllele-specific OR was not adjusted; genotype-specific ORs were adjusted for
age and gender.
cP value from unconditional logistic regression analyses.
dTrend test was calculated using the genotype as an ordinal variable in the
regression model.
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G*Power3 (http://www.psycho.uni-duesseldorf.de/abtei-
lungen/aap/gpower3). It showed that with a sample size
1052 (236 glioblastoma cases and 816 controls), the
study had > 90% power in detecting associations of
rs1760944 polymorphism with risk of glioblastoma, at a
significance level of 0.05 (df = 2).
Discussion
In this case-control study, we investigated the role of a
-141T/G variant (rs1760944) in the APE1/Ref-1 promo-
ter in 766 glioma patients and 824 cancer-free controls.
We did not observe that rs1760944 T/G SNP was signif-
icantly associated with all gliomas. However, our find-
ings indicated a protective effect of rs1760944 GG
genotype in glioblastoma. To our knowledge, this is the
first genetic epidemiological study on the association
between the APE1/Ref-1 -141T/G polymorphism and
risk of gliomas. These findings suggested that the var-
iant APE1/Ref-1 -141GG genotype may not play a major
role in the etiology of gliomas but may contribute to a
subtype of gliomas.
Recently, two independent research groups have
reported the association between the APE1/Ref-1 -141T/
Table 4 Associations between APE1/Ref-1 rs1760944 and risk of different histological types of gliomas
rs1760944 Controls
(824)
Glioblastoma (241) Astrocytomas (284) Other gliomas (241)
No. (%) No. (%) P
a OR (95% CI)
b
P
c No. (%) P
a OR (95% CI)
b P
c No. (%) P
a OR (95% CI)
b P
c
Alleles
T 898 (55.0) 286
(60.6)
0.032 1.00
(reference)
0.032 309
(55.6)
0.821 1.00
(reference)
0.821 263
(55.7)
0.783 1.00
(reference)
0.783
G 734 (45.0) 186
(39.4)
0.80
(0.65-0.98)
247
(44.4)
0.98
(0.81-1.19)
209
(44.3)
0.97
(0.79-1.19)
Genotypes
TT 237 (29.0) 81 (34.3) 0.041 1.00
(reference)
86 (30.9) 0.634 1.00
(reference)
66 (28.0) 0.592 1.00
(reference)
TG 424 (52.0) 124
(52.6)
0.84
(0.60-1.17)
0.298 137
(49.3)
0.87
(0.64-1.19)
0.390 131
(55.5)
1.11
(0.79-1.56)
0.539
GG 155 (19.0) 31 (13.1) 0.54
(0.34-0.87)
0.012 55 (19.8) 0.99
(0.66-1.47)
0.950 39 (16.5) 0.91
(0.58-1.43)
0.686
P
d for trend = 0.014 P
d for trend = 0.832 P
d for trend = 0.813
aAllele and genotype frequencies in cases and controls were compared using c
2 test.
bAllele-specific ORs were not adjusted; genotype-specific ORs were adjusted for age and gender.
cP value from unconditional logistic regression analyses.
dTrend tests were calculated using the genotype as an ordinal variable in the regression model.
Table 3 Stratified analysis of associations between APE1/Ref-1 rs1760944 genotypes and risk of all gliomas by age,
gender, smoking status, and family history of cancer
Variable Cases
a/Controls (766/824) Adjusted OR (95% CI)
b
TT TG GG TG versus TT GG versus TT
Age (years)
≤18 19/15 28/38 9/7 0.58 (0.26-1.32) 1.12
>18 214/222 364/386 116/148 0.97 (0.77-1.29) 0.80 (0.59-1.10)
Gender
Male 133/150 233/241 76/92 1.09 (0.81-1.46) 0.63 (0.47-0.85)
Female 100/87 159/183 49/63 0.72 (0.47-1.09) 0.93 (0.63-1.37)
Smoking status
Non-smokers 122/140 202/248 61/94 0.91 (0.67-1.25) 0.74 (0.50-1.12)
Former smokers 23/32 39/66 13/22 0.82 (0.41-1.62) 0.77 (0.32-1.87)
Current smokers 45/61 93/100 24/37 1.25 (0.77-2.03) 0.87 (0.46-1.67)
Family history of cancer
No 156/175 250/323 81/119 0.87 (0.66-1.15) 0.76 (0.53-1.10)
Yes 31/39 80/52 15/23 1.82 (1.01-3.28) 0.82 (0.37-1.83)
aTotal glioma patients including glioblastoma multiform, astrocytomas and other gliomas.
bAdjusted for age and gender.
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[ 2 8 ]f o u n dt h a tt h ev a r i a n tAPE1/Ref-1 -141TG or GG
genotype was associated with a significantly decreased
risk compared with TT homozygote in a hospital-based
case-control study including 730 lung cancer cases and
730 cancer-free controls in Taiwan. Furthermore, the
decreased risk was observed among the heavy smokers,
but not among the light or never smokers, which
reflected a gene-smoking interaction in the development
of lung cancer. In two studies comprising a total of
1072 lung cancer patients and 1064 cancer-free controls
in Chinese populations, Lu et al. [29] at nearly the same
time reported that the similar protective effect of the
APE1/Ref-1 -141GG genotype against lung cancer risk,
particularly among old subjects, current smokers, and
subjects with a positive family history of cancer in their
first-degree relatives. These data suggested that these
variables may modify the effect of the -141T/G poly-
morphism on lung cancer. However, such gene-environ-
ment interactions were not observed in our study. Given
that smoking is not associated with gliomas [2], one
would not necessarily expect any effect modification of
the SNP effect by smoking.
In this current study, the genetic effect of -141GG
genotype was observed for glioblastoma (WHO grade
IV), but not for other gliomas. Our interpretation of the
r e s u l t si st h a td i f f e r e n tg l ioma subtypes or grades may
be potentially involved with variable molecular and
genetic events. Similar observations have been reported
by Shete et al. [33] and Simon et al. [34]. These findings
reflected the possible existence of differential genetic
susceptibility profiles for different glioma subtypes. Our
results suggested that the APE1 m a yb eap o s s i b l em a r -
ker of susceptibility to glioblastoma vs. other gliomas.
On the other hand, the preliminary finding may be
attained through chance alone since the observed asso-
ciation was not noteworthy (FPRP = 0.643) assuming a
prior of 1%.
APE1/Ref-1 has been implicated in the development
and progression of various cancers [35-38]. A previous
study has demonstrated that substantial elevation of AP
endo activity, as well as APE/Ref-1 levels, is characteris-
tic of adult gliomas [38]. And AP endo activity is signifi-
cantly greater in high-grade than in low-grade tumors.
Therefore, while the functional role of APE1/Ref-1 in
gliomas is not completely understood, a biological rele-
vance in glioblastoma seems highly plausible. The
APE1/Ref-1 -141T/G variant was located in the promo-
ter of the gene, only 141-bp upstream from the tran-
scription initiation site. It is known that the promoter
and 3’UTR regions of a gene have functions in regulat-
ing transcription, mRNA stability, and gene production
[39]. Variants in the promoter region may function by
modulating gene transcription and leading to abnormal
protein expression [40,41]. The functional effect of the
APE1/Ref-1 -141T/G polymorphism has been reported
in lung cancer [28,29]. In this study, our results do not
disclose whether -141T/G polymorphism is correlated
with APE/Ref-1 expression level or functions in glioblas-
tom. Thus, more extensive studies are needed to resolve
the functions of the -141T/G polymorphism. Neverthe-
less, we cannot at this time rule out the possibility
that the genetic interactions between APE1/Ref-1
variants and other DNA repair genes are involved in
glioblastoma.
Previous studies on the association between APE1/Ref-
1 polymorphisms and risk of gliomas or its subtypes
only evaluated the nonsynonymous SNP rs1130409
[19,22]; however, the findings were inconsistent. Liu
et al [19] reported that the homozygous AA genotype of
rs1130409 was associated with a reduced risk of gliomas
in 373 glioma Caucasian cases and 365 Caucasian con-
trols. The protective effect of rs1130409 was more evi-
dent in high-grade glioma (i.e. glioblastoma). However,
the association of rs1130409 with glioblastoma was not
replicated in a larger study including 1,015 glioblastoma
cases and 1,994 controls [22]. The discrepancies in find-
ings between two studies may reflect chance associations
and/or differences in characteristics of the study popula-
tions. Considering our glioma sample size was not large,
we did not examine rs1130409 in the current study.
Many other studies have investigated the role of DNA
repair genes in gliomas or its subtypes [42-47]. Unfortu-
nately, few studies have been able to repeat the results
of other studies. Recently, Liu et al [48] reported that
some polymorphisms in DNA repair genes were asso-
ciated with glioblastoma survival. However, the role of
APE1/Ref-1 polymorphisms in glioma survival need to
be further investigated.
Two recent genome-wide association (GWA) studies
with risk of gliomas did not identify an association
between the rs1760944 polymorphism and glioma risk
[33,49]. The contradictory findings between GWA stu-
dies and our present study might be due to differences
between populations or the different reporting criteria
for a P value. Patients of GWA studies were whites
from North America and European, and the allele and
genotype frequencies described in the HapMap project
for the rs1760944 polymorphism are different in CEU
and CHB populations. However, these hypotheses can
only be tested in GWA studies of gliomas in Chinese
population.
Our study has several limitations. Mostly notably, the
observed association in glioblastoma alone may be a
subgroup finding due to chance. Therefore the finding
requires validation in other independent cohorts. Sec-
ondly, our study did not provide any mechanistic infor-
mation regarding glioma risk or protection. Specifically,
Zhou et al. BMC Cancer 2011, 11:104
http://www.biomedcentral.com/1471-2407/11/104
Page 6 of 8we did not determine if the AEP1/Ref-1 promoter var-
iant was correlated with the AEP1/Ref-1 expression or
its protein activity. Third, we only evaluated one SNP in
the AEP1/Ref-1 gene, which was not sufficient to sys-
tematically evaluate glioma risk for the studied gene. It
should be pointed out that our observed association
could be due to linkage disequilibrium with the true
causal SNP in or outside the AEP1/Ref-1 gene. In addi-
tion, we did not evaluate the gene-environment interac-
tions in glioblastoma since the number of glioblastoma
patients was small. However, replication of the finding
should be warranted before proceeding to the gene-
environment studies.
Conclusions
This study suggests a decreased risk of glioblastoma
associated with a specific APE1/Ref-1 genotype in a Chi-
nese Han population. Large-scale studies with ethnically
diverse populations and functional evaluation are war-
ranted to confirm our findings and to further elucidate
the significance of the variant in glioblastoma.
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